Cara Therapeutics, Inc. - Common Stock (CARA)
4.9500
-0.1500 (-2.94%)
NASDAQ · Last Trade: Apr 3rd, 4:13 PM EDT
Detailed Quote
Previous Close | 5.100 |
---|---|
Open | 5.080 |
Bid | 4.950 |
Ask | 5.010 |
Day's Range | 4.925 - 5.090 |
52 Week Range | 2.708 - 11.39 |
Volume | 22,484 |
Market Cap | 271.53M |
PE Ratio (TTM) | -0.3185 |
EPS (TTM) | -15.5 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 11,738 |
Chart
About Cara Therapeutics, Inc. - Common Stock (CARA)
Cara Therapeutics is a biopharmaceutical company focused on developing innovative therapies for pain and pruritus, utilizing its proprietary technology to create selective kappa opioid receptor agonists. The company's research aims to address unmet medical needs in various conditions, including chronic pain and inflammatory diseases, by leveraging its scientific expertise to discover and advance new treatment options. Through its commitment to improving patient outcomes, Cara Therapeutics seeks to transform the way pain and related symptoms are managed in healthcare settings. Read More
News & Press Releases
Via Benzinga · April 1, 2025
Via Benzinga · March 13, 2025

Via Benzinga · March 11, 2025

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Cara shareholders.
By Kahn Swick & Foti, LLC · Via Business Wire · February 20, 2025

Via Benzinga · January 20, 2025

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Cara shareholders.
By Kahn Swick & Foti, LLC · Via Business Wire · January 6, 2025

Via Benzinga · January 1, 2025

Via Benzinga · December 20, 2024

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · December 19, 2024

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Cara Therapeutics, Inc. (NASDAQ: CARA) and Tvardi Therapeutics, Inc. is fair to Cara shareholders. Upon completion of the proposed transaction, Cara shareholders are expected to own approximately 17.0% of the combined company.
By Halper Sadeh LLC · Via Business Wire · December 18, 2024

Ademi LLP is investigating Cara (NASDAQ: CARA) for possible breaches of fiduciary duty and other violations of law in its transaction with Tvardi.
By Ademi LLP · Via Business Wire · December 18, 2024

Via Benzinga · November 29, 2024